ABSTRACT One hundred and three patients with small cell lung carcinoma were stratified according to stage of disese (47 limited disease, 56 extensive disease) and then randomised to receive etoposide 300 mg/m2 alone for two days or a combination (VAC) of vincristine 1 mg/m2, doxorubicin (Adriamycin) 50 mg/m2, and cyclophosphamide 1000 mg/m2. The drugs were given at three week intervals. Patients were assessed after three cycles of treatment and continued with the same regimen if in complete remission and with the alternative regimen if in partial remission; they were withdrawn if the disease had progressed. Twenty four patients (23%) achieved complete remission and this occurred more often when patients were receiving VAC (19 of 82) than etoposide (5 of 75). There was no difference, however, in overall survival between those initially treated with etoposide and those having combination chemotherapy, whether for limited disease (both 8 months) or extensive disease (7 and 5 5 months). Toxicity was less with etoposide. Survival was disappointing, especially with limited disease, even in patients who showed a complete response to treatment.
Introduction
Small cell lung cancer disseminates early and is generally treated with chemotherapy rather than surgery or radiotherapy. Widely varying chemotherapeutic regimens have been used and response rates are high.' Relapse is common, however, and most patients die from their disease. A complete response to treatment is associated with prolonged survival and treatment regimens have become more complex and aggressive in the hope of increasing the proportion of patients achieving a complete response. The toxicity of these regimens, however, is such that their use is questionable for all but a few selected patients; for most patients treatment offers palliation rather than cure. Small cell lung cancer is therefore often treated with less toxic, easily manageable, outpatient Accepted 9 December 1988 regimens. We have evaluated the response and survival of patients with small cell lung cancer using two simple treatment regimens in a comparative study: a combination of vincristine, doxorubicin (Adriamycin), and cyclophosphamide (VAC), which is relatively safe but unpleasant because of gastrointestinal side effects and hair loss2; and a single agent regimen using the podophyllotoxin derivative etoposide, one of the most active drugs against small cell lung cancer,3 which may be less toxic. The comparison was made in a randomised study with a crossover design, so that patients not responding completely to one treatment were not denied the possibility of a response to the other.
Methods
Ethical approval was granted by the district ethical committees and informed consent was obtained from patients participating in the study.
Patients Ofthe 47 patients with limited disease, 25 were initially randomised to receive etoposide. After three courses of treatment three patients were in complete and 13 in partial remission (combined response rate 64%). Five patients with progressive disease were withdrawn. Of the remaining 20 patients, 17 were given VAC and three of these were in complete remission after three courses of treatment. Twenty two patients with limited disease were initially randomised to receive VAC. After three courses oftreatment five patients were in complete and 10 in partial remission (combined response rate 68%). Four patients with progressive disease were withdrawn. Of the remaining 18 patients 13 were given etoposide and one of these patients was in complete remission after three courses of treatment.
Complete remission was attributable to VAC in eight patients and to etoposide in four, the overall rate being 25%. The median survival for both treatment groups was eight months. Actuarial survival curves are shown in figure 1.
EXTENSIVE DISEASE
Of the 56 patients with extensive disease, 26 were initially randomised to receive etoposide. After three courses of treatment one patient was in complete and six in partial remission (combined response rate 27%).
Twelve patients with progressive disease were withdrawn. Of the remaining 14 patients, 13 were given VAC and a further four patients were in complete remission after three courses of treatment.
Of the 30 patients initially randomised to receive VAC, seven patients were in complete and nine in partial remission (combined response rate 53%) after three courses of treatment. Twelve patients with progressive disease were withdrawn. Eleven of the remaining 18 patients were given etoposide but none had achieved a complete response after three courses of treatment. 
